Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free MDWD Stock Alerts

MediWound (MDWD) Financials

MediWound logo
$14.29 -0.42 (-2.86%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$14.33 +0.04 (+0.28%)
As of 07/10/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for MediWound

Annual Income Statements for MediWound

This table shows MediWound's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -19 -37 -1.06 4.96 -9.20 -14 -20 -6.72 -30 -24
Consolidated Net Income / (Loss)		 -22 -19 -22 -1.06 4.96 -9.20 -14 -20 -6.72 -30 -24
Net Income / (Loss) Continuing Operations		 -22 -19 -15 -5.67 2.07 -9.28 -14 -20 -6.72 -30 -24
Total Pre-Tax Income 		-22 -19 -15 -5.67 2.07 -9.28 -14 -20 -6.53 -30 -24
Total Operating Income		 -21 -20 -14 -11 4.49 -8.84 -11 -8.35 -6.53 -17 -21
Total Gross Profit		 -1.92 -0.60 0.92 1.31 20 7.55 8.77 13 3.58 2.63 3.25
Total Revenue		 0.60 1.56 2.50 3.40 28 22 24 26 23 22 21
Operating Revenue		 0.60 1.56 2.50 3.40 28 22 24 26 23 22 21
Total Cost of Revenue		 2.52 2.16 1.58 2.84 12 14 15 13 15 18 14
Operating Cost of Revenue		 2.52 2.16 1.58 2.84 12 14 15 13 15 18 14
Total Operating Expenses		 19 20 15 12 11 16 20 22 14 22 29
Selling, General & Admin Expense		 4.00 4.08 3.78 3.80 5.24 5.46 6.35 6.92 6.77 8.20 8.45
Marketing Expense		 9.28 8.40 5.36 4.19 - 3.23 3.39 3.73 - 4.94 5.77
Research & Development Expense		 6.02 7.07 5.46 4.07 4.97 7.70 10 10 7.47 8.88 14
Other Operating Expenses / (Income)		 - - - - 1.17 - 0.00 0.68 -0.21 0.02 -0.01
Total Other Income / (Expense), net		 -0.44 1.27 -0.85 5.83 -2.43 -0.44 -2.30 -11 0.00 -13 -2.46
Interest Expense		 1.50 0.90 1.25 2.12 - 1.28 2.31 12 - 13 2.46
Income Tax Expense		 - - - - - 0.00 0.03 0.08 0.19 0.06 0.17
Weighted Average Basic Shares Outstanding		 - - 27.05M 27.18M 27.18M 3.88M 3.89M 4.99M 9.01M 9.96M 11.38M
Weighted Average Diluted Shares Outstanding		 - - 27.05M 27.18M 27.18M 27.21M 3.89M 4.99M 9.01M 9.96M 11.38M
Weighted Average Basic & Diluted Shares Outstanding		 - - 27.05M 27.18M 27.18M 27.21M 27.24M 7.24M 18.03M 10.79M 12.84M

Quarterly Income Statements for MediWound

No quarterly income statements for MediWound are available.

Annual Cash Flow Statements for MediWound

This table details how cash moves in and out of MediWound's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 -14 7.20 -29 6.20 10 -6.33 -24 -35 -33 -28
Net Cash From Operating Activities		 -20 -16 -16 -12 8.29 -6.90 -8.92 -23 1.21 -24 -12
Net Cash From Continuing Operating Activities		 -20 -16 -15 -12 9.89 -6.70 -8.04 -23 1.21 -24 -12
Net Income / (Loss) Continuing Operations		 -22 -19 -15 -5.67 2.07 -9.28 -14 -20 -4.49 -28 -22
Consolidated Net Income / (Loss)		 -22 -19 -22 -1.06 4.96 -9.20 -14 -20 -4.49 -28 -22
Depreciation Expense		 0.50 0.59 0.57 0.58 1.15 1.09 1.24 1.27 1.30 1.48 1.86
Non-Cash Adjustments To Reconcile Net Income		 1.68 1.04 1.18 1.17 2.34 0.81 2.12 -6.02 5.83 2.27 6.67
Changes in Operating Assets and Liabilities, net		 -0.89 3.12 -2.27 -0.83 4.14 0.45 2.16 0.80 -1.44 0.89 1.29
Net Cash From Investing Activities		 36 1.82 0.44 -17 -6.90 17 3.55 -0.56 -6.46 -6.27 -5.51
Net Cash From Continuing Investing Activities		 36 1.82 0.44 -17 -5.66 0.00 3.55 -0.56 -6.46 -6.27 -5.51
Sale of Property, Plant & Equipment		 - - - - - - - -0.56 -6.46 -6.27 -5.51
Net Cash From Financing Activities		 0.78 0.91 23 0.00 -0.63 -0.51 -0.69 0.00 -30 -3.17 -10
Net Cash From Continuing Financing Activities		 0.78 0.91 23 0.05 -1.01 -0.63 -0.69 0.00 -30 -3.17 -10
Repayment of Debt		 - - 0.00 0.00 -0.63 -0.51 -0.69 0.00 -30 -4.38 -14
Other Financing Activities, net		 0.03 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 1.21 3.63
Cash Interest Received		 - - - - - - - 0.07 1.95 2.25 1.59

Quarterly Cash Flow Statements for MediWound

No quarterly cash flow statements for MediWound are available.

Annual Balance Sheets for MediWound

This table presents MediWound's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 36 44 35 41 31 20 50 66 73 86
Total Current Assets		 34 42 33 36 26 15 46 50 52 60
Cash & Equivalents		 29 36 6.72 7.24 17 11 34 12 9.16 4.80
Short-Term Investments		 - - - - 4.02 - 0.00 30 34 48
Accounts Receivable		 2.74 3.57 7.40 4.56 3.23 2.71 9.98 5.14 6.31 2.73
Inventories, net		 0.84 1.89 1.68 1.61 1.38 1.20 1.96 2.85 2.69 4.09
Plant, Property, & Equipment, net		 1.28 1.92 2.02 2.30 2.63 2.48 2.37 9.23 14 19
Plant, Property & Equipment, gross		 1.28 1.92 - - 2.63 2.48 2.37 9.23 14 19
Total Noncurrent Assets		 2.04 0.69 17 25 2.25 2.31 1.81 7.54 7.20 7.65
Noncurrent Note & Lease Receivables		 - - - - 0.00 0.47 0.18 0.23 0.00 0.03
Intangible Assets		 0.77 0.64 0.50 0.43 0.36 0.30 0.23 0.17 0.10 0.03
Other Noncurrent Operating Assets		 1.27 0.06 17 24 1.88 1.55 1.40 7.14 7.10 7.59
Total Liabilities & Shareholders' Equity		 36 44 35 41 31 20 50 66 73 86
Total Liabilities		 28 35 26 25 24 24 39 35 42 43
Total Current Liabilities		 5.38 5.43 4.90 10 8.27 11 12 18 27 26
Accounts Payable		 5.38 5.43 4.75 9.80 5.85 8.31 9.82 9.42 8.84 12
Total Noncurrent Liabilities		 23 29 21 15 16 14 27 17 16 17
Capital Lease Obligations		 - - 0.00 2.01 1.74 1.39 0.85 6.35 6.51 8.15
Noncurrent Employee Benefit Liabilities		 0.22 0.33 0.35 0.24 0.29 0.29 0.36 0.46 0.40 0.47
Total Equity & Noncontrolling Interests		 7.77 9.62 8.97 15 7.27 -4.58 11 32 31 44
Total Preferred & Common Equity		 7.77 9.62 8.97 15 7.27 -4.56 11 32 31 44
Preferred Stock		 115 139 - - 142 144 179 206 236 272
Total Common Equity		 -107 -129 8.97 15 -135 -148 -168 -175 -205 -229
Common Stock		 0.06 0.08 0.08 0.08 0.08 0.08 0.14 0.18 0.22 0.26
Retained Earnings		 -107 -129 -131 -126 -135 -149 -168 -175 -205 -229

Quarterly Balance Sheets for MediWound

No quarterly balance sheets for MediWound are available.

Annual Metrics And Ratios for MediWound

This table displays calculated financial ratios and metrics derived from MediWound's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - 0.00 27,047,737.00 27,178,839.00 27,202,795.00 27,236,752.00 27,272,818.00 7,240,020.00 9,221,764.00 - 12,835,148.00
DEI Adjusted Shares Outstanding		 - 0.00 3,863,962.00 3,882,691.00 3,886,114.00 3,890,965.00 3,896,117.00 7,240,020.00 9,221,764.00 - 12,835,148.00
DEI Earnings Per Adjusted Shares Outstanding		 - 0.00 -9.49 -0.27 1.28 -2.36 -3.48 -2.71 -0.73 - -1.86
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -15 -14 -9.58 -8.05 4.49 -6.19 -7.85 -5.84 -4.57 -14 -15
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -49.67% -12.05% -36.05% -28.72%
Earnings before Interest and Taxes (EBIT)		 -21 -20 -14 -3.96 2.07 -8.84 -11 -8.35 -6.53 -19 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -20 -13 -3.38 3.22 -7.75 -9.98 -7.07 -5.23 -18 -19
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 6.99 -4.23 -37 -3.09 12 -13 2.78 -30 -22 -14
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -21 -26 2.17 9.75 -8.92 -3.83 -12 13 21 20
Increase / (Decrease) in Invested Capital		 0.00 -21 -5.35 29 7.59 -19 5.10 -8.62 25 8.47 -0.63
Book Value per Share		 $0.00 $0.00 ($4.78) $0.33 $0.56 ($4.96) ($5.45) ($6.16) ($24.12) ($22.21) ($21.19)
Tangible Book Value per Share		 $0.00 $0.00 ($4.81) $0.31 $0.54 ($4.97) ($5.46) ($6.17) ($24.14) ($22.22) ($21.19)
Total Capital		 0.00 7.77 9.62 8.97 17 9.01 -3.19 12 38 38 52
Total Debt		 0.00 0.00 0.00 0.00 2.01 1.74 1.39 0.85 6.35 6.51 8.15
Total Long-Term Debt		 0.00 0.00 0.00 0.00 2.01 1.74 1.39 0.85 6.35 6.51 8.15
Net Debt		 0.00 -29 -36 -6.81 -5.42 -20 -9.66 -33 -35 -37 -45
Capital Expenditures (CapEx)		 0.41 0.70 1.08 0.53 0.79 0.92 0.49 0.56 6.46 6.27 5.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.63 0.02 21 18 -3.66 -6.82 -0.11 -10 -18 -19
Debt-free Net Working Capital (DFNWC)		 0.00 28 36 28 25 18 4.23 34 32 26 34
Net Working Capital (NWC)		 0.00 28 36 28 25 18 4.23 34 32 26 34
Net Nonoperating Expense (NNE)		 7.23 4.78 13 -6.99 -0.46 3.01 5.70 14 2.14 17 9.00
Net Nonoperating Obligations (NNO)		 0.00 -29 -36 -6.81 -5.42 -16 0.76 -23 -19 -10 -23
Total Depreciation and Amortization (D&A)		 0.50 0.59 0.57 0.58 1.15 1.09 1.24 1.27 1.30 1.48 1.86
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($6.65) ($0.28) $1.26 ($2.38) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 3.86M 3.88M 3.89M 3.89M 3.90M 7.24M 9.01M 9.96M 11.38M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($6.65) ($0.28) $1.26 ($2.38) $0.00 $0.00 ($0.75) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 3.86M 3.88M 3.89M 3.89M 3.90M 7.24M 9.01M 9.96M 11.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($6.65) ($0.28) $1.26 ($2.38) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 3.86M 3.88M 3.89M 3.89M 3.89M 7.24M 9.22M 10.79M 12.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -14 -9.58 -8.05 3.15 -6.19 -7.85 -5.84 -4.57 -14 -15
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for MediWound

No quarterly metrics and ratios for MediWound are available.


Financials Breakdown Chart

MediWound Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MediWound's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

MediWound's net income appears to be on an upward trend, with a most recent value of -$23.88 million in 2025, rising from -$22.09 million in 2015. The previous period was -$30.22 million in 2024. Find out what analysts predict for MediWound in the coming months.

MediWound's total operating income in 2025 was -$21.25 million, based on the following breakdown:
  • Total Gross Profit: $3.25 million
  • Total Operating Expenses: $28.52 million

Over the last 10 years, MediWound's total revenue changed from $601 thousand in 2015 to $20.98 million in 2025, a change of 3,390.2%.

MediWound's total liabilities were at $42.62 million at the end of 2025, a 0.7% increase from 2024, and a 52.3% increase since 2016.

In the past 9 years, MediWound's cash and equivalents has ranged from $4.80 million in 2025 to $36.07 million in 2017, and is currently $4.80 million as of their latest financial filing in 2025.

Over the last 10 years, MediWound's book value per share changed from 0.00 in 2015 to -21.19 in 2025, a change of -2,118.7%.


Related Companies

Financial statements for NASDAQ:MDWD last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel